



Market Announcement

7 December 2022

Recce Pharmaceuticals Ltd (ASX: RCE) – Trading Halt

Description

The securities of Recce Pharmaceuticals Ltd ('RCE') will be placed in trading halt at the request of RCE, pending it releasing an announcement. Unless ASX decides otherwise, the securities will remain in trading halt until the earlier of the commencement of normal trading on Friday, 9 December 2022 or when the announcement is released to the market.

Issued by

Sean Maloney

Senior Adviser, Listings Compliance (Perth)

7 December 2022

Sean Maloney
Adviser, Listing Compliance (Perth)
Level 40 Central Park
152 - 158 St George's Terrace
Perth WA 6000

By email: tradinghaltspert@asx.com.au

Dear Sean

Recce Pharmaceuticals Ltd (ASX:RCE) – Trading halt request

Pursuant to ASX Listing Rule 17.1, Recce Pharmaceuticals Ltd ACN 124 849 065 (**Company**) requests a trading halt of the Company's securities pending the release of an announcement relating to Human Research Ethics Committee (**HREC**) Approval for a Phase II study of RECCE® 327 as a topical anti-infective therapy for Diabetic Foot Infections.

The Company requests that the trading halt be effective immediately and remain in place until the earlier of the commencement of normal trading on Friday, 9 December 2022 or the release of an announcement by the Company in relation to the HREC Approval.

The Company is not aware of any reason why the trading halt should not be granted.

For further information, please contact:

James Graham
Chief Executive Officer
+61 2 9256 2571



ASX: RCE, **FSE:** R9Q

Head Office: Level 25, 88 Phillip Street, Aurora Place, SYDNEY NSW 2000 **T** +61 (02) 9256 2571

R&D Centre - Perth: Suite 10, 3 Brodie Hall Drive, Technology Park, BENTLEY WA 6102 **T** +61 (8) 9362 9860

Washington Office: 1717 Pennsylvania Avenue NW, Suite 1025, WASHINGTON DC 20006 USA